ArticleIndian journal of psychiatry
Efficacy of ketamine therapy in the treatment of depression.
Article in Indian journal of psychiatry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 90 citations in OpenAlex.
- Trial
- Intramuscular Ketamine Pharmacokinetics in Humans: A Review.European journal of drug metabolism and pharmacokinetics · 2026Review
- Efficacy of Oral Ketamine in Patients with Depression and Suicidality: A Retrospective Study.Indian journal of psychological medicine · 2026Article
- Behavioral and psychological correlates of problematic smartphone use in street ketamine users.BMC psychology · 2025Article
- Ketamine as part of multi-modal analgesia may reduce opioid requirements following cardiac surgery: a retrospective observational cohort study.Journal of cardiothoracic surgery · 2025Observational
- The Potential of Selected Plants and Their Biologically Active Molecules in the Treatment of Depression and Anxiety Disorders.International journal of molecular sciences · 2025Review
- Insights for the Next Generation of Ketamine for the Treatment of Depressive Disorder.Journal of medicinal chemistry · 2025Review
- Aberrant glutamatergic systems underlying impulsive behaviors: Insights from clinical and preclinical research.Progress in neuro-psychopharmacology & biological psychiatry · 2024Review
- Interventional Psychiatry in India: Bridging Treatment Gaps and Expanding Horizons in Mental Health.Indian journal of psychological medicine · 2024Article
- Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms.Biomedicines · 2024Review
- Review
- Exploring Ciprofol Alternatives: A Comprehensive Review of Intravenous Anesthesia Options.Cureus · 2024Review
- Article
- Making Sense of Psychedelics in the CNS.The international journal of neuropsychopharmacology · 2024Article
- Ketamine for depressive symptoms: A retrospective chart review of a private ketamine clinic.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2024Article
- Ketamine for Chronic Pain and Mental Health: Regulations, Legalities, and the Growth of Infusion Clinics.Current pain and headache reports · 2023Review
- Interventional Mental Health: A Transdisciplinary Approach to Novel Psychiatric Care Delivery.Cureus · 2023Review
- Individual differences in the positive outcome from adolescent ketamine treatment in a female mouse model of anorexia nervosa involve drebrin A at excitatory synapses of the medial prefrontal cortex.Synapse (New York, N.Y.) · 2023Article
- Recent advancements in the practice of neuroanaesthesia and neurocritical care: An update.Indian journal of anaesthesia · 2023Article
- Sex-Specific Brain Transcriptional Signatures in Human MDD and Their Correlates in Mouse Models of Depression.Frontiers in behavioral neuroscience · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere depressive disorder is among most debilitating condition. Conventional pharmacotherapy usually takes several weeks (usually 4-12 weeks) to improve symptoms. Ketamine is an N-methyl-D aspartate receptor antagonist having rapid action on depressive symptoms.
objectivesThe effect of subanesthetic dose of ketamine was assessed on depressive and anxiety symptoms. Illness severity and improvement were assessed after treatment with ketamine. MATERIALS AND
methodsTwenty-five drug-free/naïve patients of the male sex, with severe depression having no previous history of psychotic disorder, head injury, organic disorder, cardiological problem, or substance abuse were admitted for the study. Assessments were made at baseline and injection ketamine hydrochloride was given at a subanesthetic dose of 0.5 mg/kg intravenous bolus after preparation. Assessments were repeated 1 h after the first dose. Six doses were given over 2 weeks and assessments were repeated. Final assessments were made after 1 month of the last dose.
resultsThere was a significant improvement in depression, anxiety, and the severity of illness after 2 weeks and 1 month of the last dose of ketamine. Significant improvement at 1
conclusionKetamine has a robust and rapid effect on depression, which was seen immediately after the administration of ketamine and sustained at the end of 1 month.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.